Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells

Circulation

Volumn 108, Issue 16, 2003, Pages 1930-1932

  Calabró, Paolo ^b,c   Willerson, James T ^b,c   Yeh, Edward T H ^a,b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Atherosclerosis; Inflammation; Interleukins; Muscle, smooth; Risk factors

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 6; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ARTERY MUSCLE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INFLAMMATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; UMBILICAL VEIN; ARTERIOSCLEROSIS; BIOSYNTHESIS; CELL CULTURE; CORONARY BLOOD VESSEL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; GENETICS; METABOLISM; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ARTERIOSCLEROSIS; C-REACTIVE PROTEIN; CELLS, CULTURED; CORONARY VESSELS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MUSCLE, SMOOTH, VASCULAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0142087611     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000096055.62724.C5     Document Type: Article

References (21)

1. Shah PK. Circulating markers of inflammation for vascular risk prediction: are they ready for prime time. Circulation. 2000;101:1758-1759.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
3. Ridker PM. C-reactive protein and risks of future myocardial infarction and thrombotic stroke. Eur Heart J. 1998; 19:1-3.
4. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
5. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102: 2165-2168.
6. Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001;103: 2531-2534.
7. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002;106:1439-1441.
8. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002; 106:913-919.
9. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002;105:1890-1896.
10. Yeh ET, Palusinski RP. C-reactive protein: the pawn has been promoted to queen. Curr Atheroscler Rep. 2003;5:101-105.
11. Moshage HJ, Roelofs HM, van Pelt JF, et al. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun. 1988; 155:112-117.
12. Ganter U, Arcone R, Toniatti C, et al. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. Embo J. 1989;8: 3773-3779.
13. Yasojima K, Schwab C, McGeer EG, et al. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 2000;887:80-89.
14. Jabs WJ, Logering BA, Gerke P, et al. The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol. 2003;33: 152-161.
15. Yasojima K, Schwab C, McGeer EG, et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001;158:1039-1051.
16. Yeh ET, Anderson HV, Pasceri V, et al. C-reactive protein: linking inflammation to cardiovascular complications. Circulation. 2001;104: 974-975.
17. Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 2003;107:370-371.
18. Gould JM, Weiser JN. Expression of C-reactive protein in the human respiratory tract. Infect Immun. 2001;69:1747-1754.
19. Torzewski J, Torzewski M, Bowyer DE, et al, C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386-1392.
20. Wigmore SJ, Fearon KC, Maingay JP, et al. Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes. Am J Physiol. 1997;273:E720-E726.
21. Smith JW, McDonald TL. Production of serum amyloid A and C-reactive protein by HepG2 cells stimulated with combinations of cytokines or monocyte conditioned media: the effects of prednisolone. Clin Exp Immunol. 1992;90:293-299.